This is the preview version of the Wisconsin State Legislature site.
Please see http://docs.legis.wisconsin.gov for the production version.
CSB 2.56 Addition of 4-fluoroisobutyryl fentanyl to schedule I. Section 961.14 (2) (nd) 10t., Stats., is created to read:
961.14 (2) (nd) 10t. 4-fluoroisobutyryl fentanyl (N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide);
History: cr. Affirmative action order under s. 961.11 (4), Stats., Register June 2017 No. 738, eff. 6-12-17; CR 17-089: cr. Register October 2018 No. 754, eff. 11-1-18.
CSB 2.57 Scheduling of cyclopropyl fentanyl. Section 961.14 (2) (nd) 10d., Stats., is created to read:
961.14 (2) (nd) 10d. Cyclopropyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide);
History: EmR 1716: emerg. cr. eff. 9-8-17; CR 17-0785: cr. Register July 2018 No. 751, eff. 8-1-18; corrections made under s. 35.17, Stats., Register July 2018 No. 751.
CSB 2.58 Exclusion of naldemedine. Section 961.16 (2) (a) (intro), Stats., is amended to read:
961.16 (2) (a) (intro) Opium and substances derived from opium, and any salt, compound, derivative or preparation of opium or substances derived from opium. Apomorphine, dextrorphan, nalbuphine, butorphanol, naldemedine, nalmefene, naloxegol, naloxone and naltrexone and their respective salts and the isoquinoline alkaloids of opium and their respective salts are excluded from this paragraph. The following substances, and any of their salts, isomers and salts of isomers that are theoretically possible within the specific chemical designation, are included in this paragraph:
History: cr. Affirmative action order under s. 961.11 (4), Stats., Register November 2017 No. 743, eff. 11-20-17; CR 18-024: cr. Register June 2019 No. 762, eff. 7-1-19.
CSB 2.59 Addition of ortho-fluorofentanyl to schedule I. Section 961.14 (2) (nd) 16m., Stats., is created to read:
961.14 (2) (nd) 16m. Ortho-fluorofentanyl (N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide);
History: cr. Affirmative action order under s. 961.11 (4), Stats., Register December 2017 No. 744, eff. 12-4-17; correction made under s. 35.17, Stats., Register December 2017 No. 744; CR 18-023: cr. Register June 2019 No. 762, eff. 7-1-19.
CSB 2.60 Addition of FUB-AMB to schedule I. Section 961.14 (4) (tb) 43., Stats., is created to read:
961.14 (4) (tb) 43. methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate, commonly known as FUB-AMB, MMB-FUBINACA or AMB-FUBINACA.
History: cr. Affirmative action order under s. 961.11 (4), Stats., Register December 2017 No. 744, eff. 12-11-17; correction made under s. 35.17, Stats., Register December 2017 No. 744; CR 18-022: cr. Register June 2019 No. 762, eff. 7-1-19.
CSB 2.61 Addition of MT-45 to schedule I. Section 961.14 (2) (rk), Stats., is created to read:
961.14 (2) (rk) MT-45 (1-cyclohexyl-4-(1,2-diphenylethyl)piperazine);
History: cr. Affirmative action order under s. 961.11 (4), Stats., Register January 2018 No. 745, eff. 1-22-18; correction made under s. 35.17, Stats., Register January 2018 No. 745; CR 18-069: cr. Register June 2019 No. 762, eff. 7-1-19.
CSB 2.62 Addition of para-chloroisobutyryl fentanyl to schedule I. Section 961.14 (2) (nd) 16s., Stats., is created to read:
961.14 (2) (nd) 16s. Para-chloroisobutyryl fentanyl (N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide);
History: cr. Affirmative action order under s. 961.11 (4), Stats., Register March 2018 No. 747, eff. 3-12-18; CR 18-070: cr. Register June 2019 No. 762, eff. 7-1-19.
CSB 2.63 Addition of NM2201, 5F-AB-PINACA, 4-CN-CUMYL-BUTINACA, MMB-CHMICA and 5F-CUMYL-P7AICA to schedule I. Section 961.14 (4) (tb) 44., 45., 46., 47., and 48., Stats., are created to read:
961.14 (4) (tb) 44. Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate, commonly known as NM2201.
45. N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide, commonly known as 5F-AB-PINACA.
46. 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide, commonly known as 4-CN-CUMYL-BUTINACA.
47. Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3-methylbutanoate, commonly known as MMB-CHMICA.
48. 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-pyrrolo[2,3-b]pyridine-3-carboxamide, commonly known as 5F-CUMYL-P7AICA.
History: cr. Affirmative action order under s. 961.11 (4), Stats., Register March 2018 No. 747, eff. 3-12-18; cr. Affirmative action order under s. 961.11 (4), Stats., Register August 2018 No. 752, eff. 8-13-18; correction made under s. 35.17, Stats., Register August 2018 No. 752; CR 19-010: cr. Register June 2020 No. 774, eff. 7-1-20; correction made under s. 35.17, Stats., Register June 2021 No. 786.
CSB 2.64 Addition of N-Ethylpentylone to schedule I. Section 961.14 (7) (L) 34., Stats., is created to read:
961.14 (7) (L) 34. N-Ethylpentylone, commonly known as ephylone.
History: cr. Affirmative action order under s. 961.11 (4), Stats., Register October 2018 No. 754, eff. 10-8-18; CR 19-011: cr. Register June 2020 No. 774, eff. 7-1-20.
CSB 2.65 Addition of approved cannabidiol drugs to schedule V. Section 961.22 (7), Stats., is created to read:
961.22 (7) Approved cannabidiol drugs. A drug product in finished dosage formulation that has been approved by the United States food and drug administration that contains cannabidiol (2-[1R-3-methyl-6R-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol) derived from cannabis and no more than 0.1 percent (w/w) residual tetrahydrocannabinols.
History: cr. Affirmative action order under s. 961.11 (4g), Stats., Register October 2018 No. 754, eff. 10-15-18; CR 19-012: cr. Register June 2020 No. 774, eff. 7-1-20.
CSB 2.66 Addition of 5F-EDMB-PINACA, 5F-MDMB-PICA, FUB-AKB48, 5F-CUMYL-PINACA, and FUB-144 to schedule I. Section 961.14 (4) (tb), 49., 50., 51., 52., and 53., Stats., are created to read:
961.14 (4) (tb) 49. Ethyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate, commonly known as 5F-EDMB-PINACA.
50. Methyl 2-(1-(5-fluoropentyl)-1-indole-3-carboxamido)-3,3-dimethylbutanoate, commonly known as 5F-MDMB-PICA.
51. N-(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide, commonly known as FUB-AKB48, FUB-APINACA or AKB48 N-(4-FLUOROBENZYL).
52. 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide, commonly known as 5F-CUMYL-PINACA or SGT-25.
53. (1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone, commonly known as FUB-144.
History: cr. Affirmative action order under s. 961.11 (4), Stats., Register March 2019 No. 759, eff. 3-11-19; CR 20-048: cr. Register June 2021 No. 786, eff. 7-1-21.
CSB 2.67 Addition of Brexanolone and Solriamfetol to schedule IV. Section 961.20 (2) (ap) and (2m) (g), Stats., are created to read:
961.20 (2) (ap) Brexanolone;
(2m) (g) Solriamfetol.
History: cr. Affirmative action order under s. 961.11 (4), Stats., Register July 2019 No. 763, eff. 7-22-19; CR 20-049: cr. Register June 2021 No. 786, eff. 7-1-21; correction in (2) (ap) made under s. 35.17, Stats., Register June 2021 No. 785.
CSB 2.68 Addition of N-Ethylhexedrone, a-PHP, 4-MEAP, MPHP, PV8 and 4-chloro-a-PVP to schedule I. Section 961.14 (7) (L) 35. to 40., Stats., is created to read:
961.14 (7) (L) 35. N-Ethylhexedrone.
36. Alpha-pyrrolidinohexanophenone, commonly known as a-PHP.
37. 4-methyl-alpha-ethylainopentiophenone, commonly known as 4-MEAP.
38. 4’-methyl-alpha-pyrrolidinohexiophenone, commonly known as MPHP.
39. Alpha-pyrrolidinoheptaphenone, commonly known as PV8.
40. 4’-chloro-alpha-pyrrolidinovalerophenone, commonly known as 4-chloro-a-PVP.
History: cr. Affirmative action order under s. 961.11 (4g), Stats., Register August 2019 No. 764, eff. 8-19-19; CR 20-050: cr. Register June 2021 No. 786, eff. 7-1-21.
CSB 2.69 Addition of Noroxymorphone to schedule II. Section 961.16 (2) (a) 10m., Stats., is created to read:
961.16 (2) (a) 10m. Noroxymorphone.
History: cr. Affirmative action order under s. 961.11 (4), Stats., Register November 2019 No. 767, eff. 11-11-19; CR 20-051: cr. Register June 2021 No. 786, eff. 7-1-21.
CSB 2.70 Scheduling 4F-MDMB-BINACA and MMB-FUBICA. Section 961.14 (4) (tb) 38m. and 43m., Stats., are created to read:
961.14 (4) (tb) 38m. Methyl 2-(1-(4-fluorobutyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate, commonly known as 4F-MDMB-BINACA or 4F-MDMB-BUTINACA.
43m. Methyl 2-(1-(4-fluorobenzyl)-1H-indole-3-carboxamido)-3-methylbutanoate, commonly known as MMB-FUBICA or AMB-FUBICA.
History: EmR2017: emerg. cr., eff. 6-26-20; CR 20-022: cr. Register May 2021 No. 785, eff. 6-1-21.
CSB 2.71 Addition of lasmiditan to schedule V. Section 961.22 (8), Stats., is created to read:
961.22 (8). Lasmiditan [2,4,6-trifluoro-N-(6-(1-methylpiperidine-4-carbonyl)pyridine-2-yl-benzamide].
History: cr. Affirmative action order under s. 961.11 (4), Stats., Register March 2020 No.771, eff. 3-23-20; CR 20-058: cr. Register July 2021 No. 787, eff. 8-1-21.
CSB 2.72 Scheduling of isotonitazene and 1P-LSD. Section 961.14 (2) (pe) and (4) (jm), Stats., are created to read:
961.14 (2) (pe) Isotonitazene;
961.14 (4) (jm) 1-propionyl-lysergic acid diethylamide, commonly known as 1P-LSD;
History: EmR2013: emerg. cr., eff. 6-5-20; CR 20-023: cr. Register May 2021 No. 785, eff. 6-1-21; correction made under s. 35.17, Stats., Register May 2021 No. 785.
CSB 2.73 Addition of cenobamate to schedule V. Section 961.22 (9), Stats., is created to read:
961.22 (9) CENOBAMATE Cenobamate ([(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate; 2H-tetrazole-2-ethanol, alpha-(2-chlorophenyl)-, carbamate (ester), (alphaR)-; carbamic acid (R)-(+)-1-(2-chlorophenyl)-2-(2H-tetrazol-2-yl)ethyl ester)
History: cr. Affirmative action order under s. 961.11 (4), Stats., Register May 2020 No. 773, eff. 5-18-20; CR 20-075: cr. Register July 2021 No. 787, eff. 8-1-21.
CSB 2.74 Addition of Lemborexant to schedule IV. Section 961.20 (2) (eqm), Stats., is created to read:
961.20 (2) (eqm) Lemborexant.
History: cr. Affirmative action order under s. 961.11 (4), Stats., Register March 2020 No.771, eff. 5-18-20; CR 20-076: cr. Register July 2021 No. 787, eff. 8-1-21; correction made under s. 35.17, Stats., Register July 2021 No. 787.
CSB 2.75 Exclusion of approved cannabidiol drugs from schedule I. (1) Section 961.14 (4) (t) 4., Stats., is created to read:
961.14 (4) (t) 4. A drug product in finished dosage formulation that has been approved by the United States food and drug administration that contains cannabidiol (2-[1R-3-methyl-6R-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol) derived from cannabis and no more than 0.1 percent (w/w) residual tetrahydrocannabinols.
(2)  Section 961.22 (7) is repealed.
History: cr. Affirmative action order under s. 961.11 (4g), Stats., Register June 2020 No. 774, eff. 6-29-20; CR 20-077: cr. Register July 2021 No. 787, eff. 8-1-21.
CSB 2.76 Addition of norfentanyl to schedule II. (1) Section 961.16 (8) (b), Stats., is renumbered 961.16 (8) (b) (intro.) and amended to read:
961.16 (8) (b) An immediate precursor to fentanyl, including all of the following:
1. 4-anilino-N-phenethyl-4-piperidine, commonly known as ANPP.
(2)  Section 961.16 (8) (b) 2., Stats. is created to read:
2. N-phenyl-N-(piperidin-4-yl)propionamide, commonly known as norfentanyl.
History: cr. Affirmative action order under s. 961.11 (4), Stats., Register June 2020 No. 774, eff. 6-29-20; CR 20-078: cr. Register July 2021 No. 787, eff. 8-1-21.
CSB 2.77 Scheduling of flualprazolam. Section 961.20 (2) (ef), Stats., is created to read:
961.20 (2) (ef) Flualprazolam;
History: EmR1037: emerg. cr., eff. 10-27-20; CR 20-078: cr. Register July 2021 No. 787, eff. 8-1-21; correction made under s. 35.17, Stats., Register July 2021 No. 787.
CSB 2.78 Addition of crotonyl fentanyl to schedule I. Section 961.14 (2) (nd) 9m., Stats., is created to read:
961.14 (2) (nd) 9m. Crotonyl Fentanyl ((E)-N-(1-phenethylpiperidin-4-yl)-N-phenylbut-2- enamide);
History: cr. Affirmative action order under s. 961.11 (4), Stats., Register November 2020 No. 779, eff. 11-23-20; CR 22-011: cr. Register June 2023 No. 810, eff. 7-1-23; correction made under s. 35.17, Stats., Register June 2023 No. 810.
Loading...
Loading...
Published under s. 35.93, Stats. Updated on the first day of each month. Entire code is always current. The Register date on each page is the date the chapter was last published.